ESTRO 2023 - Abstract Book

S815

Monday 15 May 2023

ESTRO 2023

diagnosed brain metastases between 2006 and 2014. The aim of this study is to validate the Lung-molGPA model in an independent Asian patient population Materials and Methods Four hundred thirty-three patients (368 adenocarcinoma and 65 nonadenocarcinoma) with NSCLC with newly diagnosed brain metastasis between 2005 and 2017 were reviewed retrospectively and scored using the Lung-molGPA model.

Results The overall median survival for the cohort in the present study was 14 months (16.5 months in the adenocarcinoma and 8.0 months in the nonadenocarcinoma, respectively; p = 0.003). For patients with adenocarcinoma, the median survival for patients with a Lung-molGPA score of 3.5 to 4.0 was 44.7 months, while the median survival was only 8.9 months in patients scoring 0–1.0, 17.0 months in patients scoring 1.5–2.0, and 30.2 months for scores of 2.5–3.0 (p <0.0001). For patients with nonadenocarcinoma, the median survival for scores 0–1.0, 1.5–2.0, and 2.5–3.0 were 6.7, 10.3, and 13.2 months, respectively (p = 0.038).

Conclusion Survival for patients with NSCLC and brain metastases varies widely. This study provides an independent validation of the 2016 Lung-molGPA in Asian patients. PD-0968 Treatment of COVID-19 pneumonia with low-dose radiotherapy in frail patients B.A. Malave Chacon 1 , J.C. Acosta Arteaga 1 , B. Piqué 2 , L. Torres-Royo 1 , E. Rodríguez-Tomás 3 , R. Benavides 4 , G. De Febrer 5 , P. Araguas 1 , J.A. Gomez 1 , M. Arquez 1 , V.D. Calderon 1 , M. Algara 6 , A. Montero 7 , D. Parada 2 , F. Riu 2 , A. Jiménez 8 , C. Vasco 5 , S. Sabater 9 , J. Camps 3 , J. Joven 3 , M. Arenas Prat 10 1 Sant Joan de Reus University Hospital, Radiation Oncology, Tarragona, Spain; 2 Sant Joan de Reus University Hospital, Pathology, Tarragona, Spain; 3 Rovira i Virgili University, Biomedical Research Unit, Pere Virgili Health Research Institute, Tarragona, Spain; 4 Sant Joan de Reus University Hospital, Pere Virgili Health Research Institute. Radiation Oncology, Tarragona, Spain; 5 Sant Joan de Reus University Hospital, Geriatric and Palliative Care, Tarragona, Spain; 6 Institute of Medical Research, Hospital del Mar, Autonomous University of Barcelona, Radiation Oncology, Barcelona, Spain; 7 HM Hospitals, Radiation Oncology, Madrid, Spain; 8 Rovira i Virgili University, Pere Virgili Health Research Institute, Tarragona, Spain; 9 Complejo Hospitalario de Albacete, Radiation Oncology, Albacete, Spain; 10 Sant Joan de Reus University Hospital, Pere Virgili Health Research Institute, Rovira i Virgili University, Radiation Oncology, Tarragona, Spain Purpose or Objective To assess the efficacy of lung low-dose radiotherapy (LD-RT) in the treatment of patients with COVID-19 pneumonia. Materials and Methods Ambispective study with two cohorts to compare treatment with standard of care (SoC) plus a single dose of 0.5 Gy to the whole thorax (experimental prospective cohort) with SoC alone (control retrospective cohort) for patients with COVID-19 pneumonia, not candidates for admission to Intensive Care Unit (ICU) for mechanical ventilation. Results Fifty patients treated with LD-RT were compared with 50 matched controls. Mean age was 85 years in both groups. An increase in arterial oxygen partial pressure (PaO2)/fraction of inspired oxygen (PAFI) in the experimental LD-RT-treated group compared to the control group was observed after one month (473 vs. 302 mmHg; p<0.0001). Pulse oxymetric saturation/fraction of inspired oxygen (SAFI) values were also significantly higher in LD-RT-treated patients than control patients at one week (405 vs. 334 mmHg; p = 0.0157) and one month after LD-RT (462 vs. 326 mmHg; p<0.0001). All other time-point measurements of the respiratory parameters were similar across groups. Patients in the experimental group were discharged from the hospital significantly earlier (23 vs. 31 days; p=0.047). Fifteen and 24 patients died due to COVID 19 pneumonia in the experimental and control cohorts, respectively (30% vs. 48%; p=0.1). LD-RT was associated with a decreased Odds Ratio (OR) for one-month COVID-19 mortality (OR=0.302 [0.106 – 0.859]; p=0.025) when adjusted for potentially confounding factors. Overall survival was significantly prolonged in the LD-RT group compared with the control group (log-rank p=0.027). No adverse events related to radiation treatment have been observed.